Immunocore Completes Enrollment in Study of Potential Advanced Melanoma Treatment

07:46 AM EDT, 09/14/2026 (MT Newswires) -- Immunocore (IMCR) achieved its target enrollment of 540 patients in a phase 3 clinical trial evaluating Kimmtrak as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced melanoma whose disease has progressed following prior therapy, the company said Monday. The primary endpoint of the study is overall survival, the company said. The company expects to share topline data as soon as late 2026, it said.